BRIEF published on 07/24/2026 at 10:01, 16 days 13 hours ago BlackRock Inc. reduces its stake in IPSEN SA Voting Rights Actions BlackRock Threshold Crossing Ipsen SA
BRIEF published on 07/24/2026 at 07:05, 16 days 16 hours ago Update on Ipsen's Phase III BOLD Trial in Biliary Atresia Clinical Research Biliary Atresia Phase III BOLD Trial Odevixibat Liver Transplantation
PRESS RELEASE published on 07/24/2026 at 07:00, 16 days 16 hours ago Ipsen provides update on Phase III BOLD trial in biliary atresia Ipsen's Phase III BOLD trial for biliary atresia did not meet primary endpoint. Bylvay safety profile confirmed. Insights gained will aid future research and patient care Ipsen Biliary Atresia Phase III BOLD Trial Bylvay Pediatric Liver Transplant
BRIEF published on 07/09/2026 at 07:05, 1 month ago Dysport® Achieves Milestone in Migraine Phase III Trials Phase III Trials Dysport Episodic Migraine Chronic Migraine Botulinum Toxin
BRIEF published on 07/09/2026 at 07:05, 1 month ago Positive Phase III Results for Dysport® in the Treatment of Migraine Phase III Dysport Episodic Migraine Chronic Migraine Botulinum Toxin
PRESS RELEASE published on 07/09/2026 at 07:00, 1 month ago Dysport® is the first botulinum toxin to achieve positive topline Phase III results in both episodic and chronic migraine. Dysport® achieves positive topline Phase III results in both episodic and chronic migraine, marking a significant advancement in migraine treatment Prevention Dysport® Botulinum Toxin Phase III Results Migraine
BRIEF published on 07/06/2026 at 12:02, 1 month 3 days ago BlackRock's stake in IPSEN SA fluctuates at the 5% threshold. Share Capital Voting Rights BlackRock Threshold Crossing Ipsen SA
BRIEF published on 06/29/2026 at 07:05, 1 month 10 days ago Ipsen to Acquire Kartos Therapeutics, Enhancing Hemato-Oncology Portfolio Hemato-oncology Ipsen Acquisition Ruxolitinib Myelofibrosis Navtemadlin
PRESS RELEASE published on 06/29/2026 at 07:00, 1 month 10 days ago Ipsen to acquire Kartos Therapeutics, expanding hemato-oncology late-stage pipeline Ipsen acquires Kartos Therapeutics, adding navtemadlin, a late-stage rare blood cancer asset in Phase III, to expand its Oncology portfolio. Top-line data from Phase III trial expected in 2027 Phase III Ipsen Hemato-oncology Navtemadlin Kartos Therapeutics
BRIEF published on 05/18/2026 at 07:05, 2 months 22 days ago Ipsen Initiates New Share Buy-back Program Share Buy-back Shareholder Value Investment Strategy Employee Share Plans Euronext: IPN
Published on 08/07/2026 at 23:15, 2 days ago Faraday Copper Reports Second Quarter 2026 Financial Results
Published on 08/07/2026 at 23:00, 2 days ago Rio Grande Resources Announces up to $2,500,000 Non-Brokered Private Placement Financing
Published on 08/07/2026 at 22:30, 2 days 1 hour ago UraniumX Deploys $3.8 Million to Athabasca Basin Exploration
Published on 08/07/2026 at 22:15, 2 days 1 hour ago Noram Lithium Engages 1353656 BC Ltd. for Marketing and Management Consulting Services
Published on 08/09/2026 at 15:05, 8 hours 35 minutes ago GearUP and Escape from Tarkov Partner to Enhance Online Gaming Experience for the New Season
Published on 08/09/2026 at 00:01, 23 hours 39 minutes ago Club Offers for Travel Enthusiasts in Germany
Published on 08/08/2026 at 16:25, 1 day 7 hours ago Bybit Sues North Korea and Lazarus Group, Secures Preliminary Injunction Freezing Stolen Assets in Landmark Crypto Asset Recovery Effort
Published on 08/07/2026 at 23:21, 2 days ago EQS-Adhoc: Northern Data Group reports Q2 2026 including the adverse fair value movement on contingent consideration
Published on 08/07/2026 at 19:30, 2 days 4 hours ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 08/07/2026 at 18:54, 2 days 4 hours ago Covivio - Information on Treasury shares transactions between August 3rd, 2026, and August 7th, 2026
Published on 08/07/2026 at 18:40, 2 days 5 hours ago Disclosure of transactions in own shares from August 3 to August 7, 2026
Published on 08/07/2026 at 17:49, 2 days 5 hours ago Crédit Agricole CIB announced the publication of the Amendment of its 2025 Universal Registration Document
Published on 08/07/2026 at 08:30, 2 days 15 hours ago Disclosure of shares outstanding and voting rights - 07.08.2026
